Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

University of Athens School of Medicine, Athens, Greece.

Survival: monthsCountry:Greece
Toxiciy Grade:4City/State/Province:Athens
Treatments:ChemotherapyHospital:University of Athens School of Medicine
Drugs:Journal:Link
Date:Jan 2004

Description:

Patients: This Phase II study involved 38 patients with hormone refractory prostate cancer. Patients were divided into two groups: Group 1 and Group 2. The average age of patients in Group 1 was 73 years and the median PSA was 56 (range from .1 – 823).

Treatment: The patients in Group 1 were treated with chemotherapy – estramustine (emcyt) and etoposide (VP16, vepesid).

Toxicity: For patients in Group 1, grade 3-4 toxicities included neutropenia, anemia, thrombocytopenia, and alopecia.

Results: The median overall survival for patients in Group 1 was 18.8 months.

Correspondence: M.A. Dimopoulos, MD




Back